[go: up one dir, main page]

MX2021013354A - Metodos para tratar y/o prevenir queratosis actinica. - Google Patents

Metodos para tratar y/o prevenir queratosis actinica.

Info

Publication number
MX2021013354A
MX2021013354A MX2021013354A MX2021013354A MX2021013354A MX 2021013354 A MX2021013354 A MX 2021013354A MX 2021013354 A MX2021013354 A MX 2021013354A MX 2021013354 A MX2021013354 A MX 2021013354A MX 2021013354 A MX2021013354 A MX 2021013354A
Authority
MX
Mexico
Prior art keywords
treating
methods
actinic keratosis
preventing actinic
preventing
Prior art date
Application number
MX2021013354A
Other languages
English (en)
Inventor
Johnson Yiu- Nam LAU
Min- Fun Rudolf KWAN
E Douglas Kramer
David Lawrence Cutler
Jane Fang
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021013354(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Publication of MX2021013354A publication Critical patent/MX2021013354A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La solicitud pertenece a métodos para tratar y/o prevenir queratosis actínica, que comprende administrar una cantidad terapéuticamente efectiva de KX-01, (ver Fórmula) (I), a un sujeto que lo necesita.
MX2021013354A 2017-03-10 2019-09-09 Metodos para tratar y/o prevenir queratosis actinica. MX2021013354A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10

Publications (1)

Publication Number Publication Date
MX2021013354A true MX2021013354A (es) 2021-11-18

Family

ID=63446658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010707A MX387658B (es) 2017-03-10 2018-03-12 Métodos para tratar y/o prevenir queratosis actínica.
MX2021013354A MX2021013354A (es) 2017-03-10 2019-09-09 Metodos para tratar y/o prevenir queratosis actinica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010707A MX387658B (es) 2017-03-10 2018-03-12 Métodos para tratar y/o prevenir queratosis actínica.

Country Status (13)

Country Link
US (3) US10617693B2 (es)
EP (2) EP3592355B1 (es)
JP (3) JP7502863B2 (es)
KR (2) KR20240090837A (es)
CN (1) CN110891575A (es)
AU (1) AU2018231144B2 (es)
BR (1) BR112019018687A2 (es)
CA (1) CA3055938A1 (es)
IL (1) IL269182B2 (es)
MX (2) MX387658B (es)
TW (1) TWI841523B (es)
WO (1) WO2018165647A1 (es)
ZA (1) ZA202100106B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
AU2018231144B2 (en) * 2017-03-10 2023-12-21 Atnx Spv, Llc Methods of treating and/or preventing actinic keratosis
JP2020533412A (ja) 2017-09-07 2020-11-19 アセネックス エイチケイ イノベイティブ リミテッド ２−（５−（４−（２−モルホリノエトキシ）フェニル）ピリジン−２−イル）−ｎ−ベンジルアセトアミドの固体形態
CA3092939C (en) * 2018-03-07 2024-10-08 Atnx Spv, Llc USE OF THE COMBINATION OF KX01 AND VITAMIN D TO TREAT HYPERPROLIFERATIVE SKIN DISORDERS
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
AU2020288640A1 (en) * 2019-06-05 2021-12-23 Atnx Spv, Llc Methods of treating and/or preventing psoriasis
WO2022159778A1 (en) * 2021-01-21 2022-07-28 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CA2656564C (en) 2006-06-29 2015-06-16 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
AU2008254500B2 (en) 2007-05-17 2014-01-23 Atnx Spv, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
PL2378876T3 (pl) * 2008-12-19 2019-06-28 Medicis Pharmaceutical Corporation Dawka imikwimodu o mniejszej sile i krótkie schematy dawkowania w leczeniu rogowacenia słonecznego
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
CN112755193A (zh) 2012-06-26 2021-05-07 德玛医药 使用卫康醇或其衍生物治疗抗酪氨酸激酶抑制剂的恶性肿瘤的方法
AU2018231144B2 (en) * 2017-03-10 2023-12-21 Atnx Spv, Llc Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
EP3592355A4 (en) 2021-01-06
EP3592355B1 (en) 2025-12-10
US20200197405A1 (en) 2020-06-25
IL269182B1 (en) 2023-07-01
CA3055938A1 (en) 2018-09-13
US11497750B2 (en) 2022-11-15
AU2018231144B2 (en) 2023-12-21
RU2019131757A (ru) 2021-04-12
IL269182A (en) 2019-11-28
EP4659740A3 (en) 2026-02-18
KR20190141661A (ko) 2019-12-24
CN110891575A (zh) 2020-03-17
US10617693B2 (en) 2020-04-14
IL269182B2 (en) 2023-11-01
ZA202100106B (en) 2022-08-31
US20230172942A1 (en) 2023-06-08
TW201842913A (zh) 2018-12-16
JP2023015269A (ja) 2023-01-31
MX2019010707A (es) 2020-01-15
JP2025029010A (ja) 2025-03-05
EP3592355A1 (en) 2020-01-15
TWI841523B (zh) 2024-05-11
US20180256589A1 (en) 2018-09-13
MX387658B (es) 2025-03-18
BR112019018687A2 (pt) 2020-04-07
AU2018231144A1 (en) 2019-10-03
AU2024201828A1 (en) 2024-05-02
JP2020510042A (ja) 2020-04-02
JP7502863B2 (ja) 2024-06-19
WO2018165647A1 (en) 2018-09-13
EP4659740A2 (en) 2025-12-10
KR20240090837A (ko) 2024-06-21
RU2019131757A3 (es) 2021-05-31

Similar Documents

Publication Publication Date Title
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12019501010A1 (en) Arginase inhibitor combination therapies
WO2017059319A3 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
MX378273B (es) Compuestos activos hacia bromodominios.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
JOP20210050A1 (ar) معدلات تعبير pnpla3
SG10201909413SA (en) Method of treating medulloblastoma with an ezh2 inhibitor
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2019000677A (es) Células miméticas de células b.
MX2018014621A (es) Composicion biopesticida para uso en la prevencion o para minimizar la enfermedad de la planta.
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
WO2015112902A3 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MY200803A (en) Mpo inhibitors for use in medicine
FR3045392B1 (fr) Dispositif pour le traitement d'un sujet par combinaison notamment de la lithotherapie, la chromotherapie, la luminotherapie et la musicotherapie
MY205171A (en) Methods of treatment of hypertriglyceridemia
WO2015134603A3 (en) Methods for treating cancer
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
PH12017501918A1 (en) Multi-peptide composition